Page 130 - THE EVOLUTION OF EARLY ARTHRITIS AND CARDIOVASCULAR RISK Samina A. Turk
P. 130

CHAPTER 6
16. Charles-Schoeman C, Wang X, Lee YY, Shahbazian A, Navarro-Millan I, Yang S, et al. Association of Triple Therapy With Improvement in Cholesterol Profiles Over Two-Year Followup in the Treatment of Early Aggressive Rheumatoid Arthritis Trial. Arthritis Rheumatol 2016;68:577-86.
17. ChatterjeeS,SarkateP,GhoshS,BiswasM,GhoshA.Early,structureddiseasemodifying anti-rheumatic drug (DMARD) therapy reduces cardiovascular risk in rheumatoid arthritis- -a single centre study using non-biologic drugs. J Assoc Physicians India 2013;61:531-4.
18. Georgiadis AN, Papavasiliou EC, Lourida ES, Alamanos Y, Kostara C, Tselepis AD, et al. Atherogenic lipid profile is a feature characteristic of patients with early rheumatoid arthritis: effect of early treatment--a prospective, controlled study. Arthritis Res Ther 2006;8:R82.
19. Navarro-Millan I, Charles-Schoeman C, Yang S, Bathon JM, Bridges SL, Jr., Chen L, et al. Changes in lipoproteins associated with methotrexate or combination therapy in early rheumatoid arthritis: results from the treatment of early rheumatoid arthritis trial. Arthritis Rheum 2013;65:1430-8.
20. Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO, III, et al. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis 2010;69:1580-8.
21. Nederlands Huisartsen Genootschap. Multidisciplinary guideline on cardiovascular risk management 2011. Bohn Stafleu van Loghum, 2011.
22. BaloghE,MadrugaDJ,OrrC,MullanR,HartyL,FitzGeraldO,etal.Comparisonofremission criteria in a tumour necrosis factor inhibitor treated rheumatoid arthritis longitudinal cohort: patient global health is a confounder. Arthritis Res Ther 2013;15:R221.
23. Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics 1977 Mar;33(1):159-74.
24. Twisk J, Rijmen F. Longitudinal tobit regression: a new approach to analyze outcome variables with floor or ceiling effects. J Clin Epidemiol 2009;62:953-8.
25. Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ 2009;338:b1665.
26. ParsonsC,MuradMH,AndersenS,MookadamF,LabonteH.Theeffectofantihypertensive treatment on the incidence of stroke and cognitive decline in the elderly: a meta-analysis. Future Cardiol 2016;12:237-48.
27. SilvermanMG,FerenceBA,ImK,WiviottSD,GiuglianoRP,GrundySM,etal.Association Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions: A Systematic Review and Meta-analysis. JAMA 2016;316:1289-97.
28. Holmqvist ME, Wedren S, Jacobsson LT, Klareskog L, Nyberg F, Rantapaa-Dahlqvist S, et al. No increased occurrence of ischemic heart disease prior to the onset of rheumatoid arthritis: results from two Swedish population-based rheumatoid arthritis cohorts. Arthritis Rheum 2009;60:2861-9.
29. Holmqvist ME, Wedren S, Jacobsson LT, Klareskog L, Nyberg F, Rantapaa-Dahlqvist S, et al. Rapid increase in myocardial infarction risk following diagnosis of rheumatoid arthritis amongst patients diagnosed between 1995 and 2006. J Intern Med 2010;268:578-85.
128



















































































   128   129   130   131   132